uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone31-20-240-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.28 million
Profitability
Miscellaneous
Employees212
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Uniqure (NASDAQ:QURE) Frequently Asked Questions
What is Uniqure's stock symbol?
Uniqure trades on the NASDAQ under the ticker symbol "QURE."
How were Uniqure's earnings last quarter?
Uniqure NV (NASDAQ:QURE) announced its quarterly earnings results on Monday, July, 29th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.75) by $0.08. The biotechnology company had revenue of $2.47 million for the quarter, compared to analysts' expectations of $1.53 million. Uniqure had a negative net margin of 1,232.30% and a negative return on equity of 61.67%. View Uniqure's Earnings History.
When is Uniqure's next earnings date?
What price target have analysts set for QURE?
14 brokerages have issued 1-year target prices for Uniqure's shares. Their forecasts range from $35.00 to $100.00. On average, they anticipate Uniqure's stock price to reach $76.92 in the next twelve months. This suggests a possible upside of 83.6% from the stock's current price. View Analyst Price Targets for Uniqure.
What is the consensus analysts' recommendation for Uniqure?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 1 hold rating and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Uniqure.
What are Wall Street analysts saying about Uniqure stock?
Here are some recent quotes from research analysts about Uniqure stock:
- 1. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (10/3/2019)
- 2. HC Wainwright analysts commented, "Enrollment completion in the HOPE-B registration study positions 12+month lead. We now anticipate data during 4Q20, with likely commercial launch during 4Q21, ahead of our prior 2H-2022 expectations. We continue to believe, AMT-061 remains the one-and-done therapy of choice based on: (1) the ability to successfully treat subjects with NAB’s to the peer construct; (2) low-levels of NABs to AAV5, which is a significant commercial differentiator, compelling centers to choose a therapy that could benefit the majority of patients i.e., >90% in case of AMT-061, over one with at least 40% exclusion criteria; and (3) no prophylactic steroids." (9/3/2019)
- 3. Chardan Capital analysts commented, "We continue our bullish QURE thesis (and affirm our $175 price target) ahead of what we see as among the most compelling 2020 catalysts in biotech:." (9/3/2019)
- 4. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and $81 PT on uniQure. This morning, Spark (Neutral) filed a 14D-9, which detailed a timeline (Figure 1) of potential partnership and acquisition talks the company had. Our key takeaway is that four parties, including Roche (RHHBY – NC) were in discussions regarding a co- development and co-promotion partnership relating to hemophilia A. Three of these parties (including Roche) were involved in acquisition talks. This detailed process indicates there is an immense interest in hemophilia gene therapy programs from pharma." (3/7/2019)
Has Uniqure been receiving favorable news coverage?
News coverage about QURE stock has trended negative on Monday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Uniqure earned a news impact score of -2.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Uniqure.
Are investors shorting Uniqure?
Uniqure saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 3,670,000 shares, an increase of 14.0% from the August 30th total of 3,220,000 shares. Based on an average daily trading volume, of 593,400 shares, the short-interest ratio is currently 6.2 days. Currently, 11.6% of the shares of the stock are sold short. View Uniqure's Current Options Chain.
Who are some of Uniqure's key competitors?
Some companies that are related to Uniqure include Dr.Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Beigene (BGNE), Amarin (AMRN), Horizon Therapeutics (HZNP), The Medicines (MDCO), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), Evotec (EVTCY), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR) and Mirati Therapeutics (MRTX).
What other stocks do shareholders of Uniqure own?
Who are Uniqure's key executives?
Uniqure's management team includes the folowing people:
- Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 47)
- Dr. Sander van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & GM of Amsterdam (Age 65)
- Mr. Jonathan Garen, Chief Bus. Officer (Age 53)
- Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
- Dr. Scott T. McMillan, Chief Operations Officer (Age 60)
Who are Uniqure's major shareholders?
Uniqure's stock is owned by many different of institutional and retail investors. Top institutional investors include Henry James International Management Inc. (0.30%). Company insiders that own Uniqure stock include Alexander Edward Kuta III, Christian Klemt, David Schaffer, Deventer Sander Van, Jeremy P Springhorn, Maria E Cantor, Matthew C Kapusta, Philip Astley-Sparke, Robert Gut, Scott T Mcmillan and Steven Zelenkofske. View Institutional Ownership Trends for Uniqure.
Which major investors are buying Uniqure stock?
How do I buy shares of Uniqure?
Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Uniqure's stock price today?
One share of QURE stock can currently be purchased for approximately $41.90.
How big of a company is Uniqure?
Uniqure has a market capitalization of $1.59 billion and generates $11.28 million in revenue each year. The biotechnology company earns $-83,300,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Uniqure employs 212 workers across the globe.View Additional Information About Uniqure.
What is Uniqure's official website?
How can I contact Uniqure?
Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected]
MarketBeat Community Rating for Uniqure (NASDAQ QURE)
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
